Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged virus, which causes mild to severe pneumonia(Wang, Horby, Hayden & Gao, 2020). One of the most commonly used first-line treatment in COVID-19 disease is hydroxychloroquine (HCQ) with or without azithromycin (AZT)(Yao et al., 2020). The HCQ may have a role between ACE-2 receptor and SARS-COV-2 attachment and may decrease pro-inflammatory response(Tripathy, Dassarma, Roy, Chabalala & Matsabisa, 2020).